SCHEMBL8113196

SCHEMBL8113196

Bc1ccc(CCC(=O)OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
F2RL1 P55085 1/20 0.49
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
IDO1 P14902 1/20 0.47
EPHX2 P34913 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27804228 0.98 CYP4F2 (0.49) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL22922181 0.90 CYP4F2 (0.59) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL12419941 0.82 CYP4F2 (0.53) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL8508610 0.82 CYP4F2 (0.53) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL1587088 0.82 FFAR1 (0.59) CYP4F2CYP4A11F2RL1ALDH1A1LMNA
SCHEMBL1410420 0.82 CYP4A11 (0.56) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL3679325 0.82 CYP4A11 (0.72) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL2569441 0.82 L3MBTL1 (0.55) CYP4F2CYP4A11F2RL1ADRB2ADRB1
4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL95254 0.82 HDAC2 (0.53) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL7930119 0.81 ADRB2 (0.52) CYP4F2CYP4A11F2RL1ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3334721-B1 CGRP RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2021-04-28 EP disclosed
WO-2017027345-A1 CGRP RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2017-02-16 WO disclosed
US-9108989-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-08-18 US disclosed
US-20140121183-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8629125-B2 Inhibitors of fatty acid amide hydrolase Infinty Pharmaceuticals, Inc. (US) 2014-01-14 US disclosed
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-8349814-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-01-08 US disclosed
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE ADAMS JULIAN 2011-09-22 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121183-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP4F2 658/4885CYP4A11 639/4885F2RL1 205/4885
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP4F2 658/4885CYP4A11 639/4885F2RL1 205/4885
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP4F2 658/4885CYP4A11 639/4885F2RL1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.